Literature DB >> 8955115

The structural basis of monoclonal antibody Alz50's selectivity for Alzheimer's disease pathology.

G Carmel1, E M Mager, L I Binder, J Kuret.   

Abstract

The epitope on tau protein recognized by the monoclonal antibody Alz50 was defined through internal deletion mutagenesis and quantified by affinity measurements. The epitope is discontinuous and requires both a previously identified N-terminal segment and the microtubule binding region for efficient binding of Alz50. The interaction between these regions is consistent with an intramolecular reaction mechanism, suggesting that Alz50 binding depends on the conformation of individual tau monomers. The results suggest that tau adopts a distinct conformation when polymerized into filaments and that this conformation is recognized selectively by Alz50.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8955115     DOI: 10.1074/jbc.271.51.32789

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  133 in total

1.  Structural analysis of Pick's disease-derived and in vitro-assembled tau filaments.

Authors:  M E King; N Ghoshal; J S Wall; L I Binder; H Ksiezak-Reding
Journal:  Am J Pathol       Date:  2001-04       Impact factor: 4.307

2.  Energy metabolism and protein phosphorylation during apoptosis: a phosphorylation study of tau and high-molecular-weight tau in differentiated PC12 cells.

Authors:  P K Davis; G V Johnson
Journal:  Biochem J       Date:  1999-05-15       Impact factor: 3.857

3.  Rac1b increases with progressive tau pathology within cholinergic nucleus basalis neurons in Alzheimer's disease.

Authors:  Sylvia E Perez; Damianka P Getova; Bin He; Scott E Counts; Changiz Geula; Laurent Desire; Severine Coutadeur; Helene Peillon; Stephen D Ginsberg; Elliott J Mufson
Journal:  Am J Pathol       Date:  2011-12-03       Impact factor: 4.307

4.  Tyrosine nitration within the proline-rich region of Tau in Alzheimer's disease.

Authors:  Juan F Reyes; Yifan Fu; Laurel Vana; Nicholas M Kanaan; Lester I Binder
Journal:  Am J Pathol       Date:  2011-05       Impact factor: 4.307

5.  Prominent axonopathy in the brain and spinal cord of transgenic mice overexpressing four-repeat human tau protein.

Authors:  K Spittaels; C Van den Haute; J Van Dorpe; K Bruynseels; K Vandezande; I Laenen; H Geerts; M Mercken; R Sciot; A Van Lommel; R Loos; F Van Leuven
Journal:  Am J Pathol       Date:  1999-12       Impact factor: 4.307

6.  Truncation of tau at E391 promotes early pathologic changes in transgenic mice.

Authors:  Pamela J McMillan; Brian C Kraemer; Linda Robinson; James B Leverenz; Murray Raskind; Gerard Schellenberg
Journal:  J Neuropathol Exp Neurol       Date:  2011-11       Impact factor: 3.685

7.  Differentiating Alzheimer disease-associated aggregates with small molecules.

Authors:  Nicolette S Honson; Ronald L Johnson; Wenwei Huang; James Inglese; Christopher P Austin; Jeff Kuret
Journal:  Neurobiol Dis       Date:  2007-07-28       Impact factor: 5.996

8.  Aging analysis reveals slowed tau turnover and enhanced stress response in a mouse model of tauopathy.

Authors:  Chad Dickey; Clara Kraft; Umesh Jinwal; John Koren; Amelia Johnson; Laura Anderson; Lori Lebson; Daniel Lee; Dennis Dickson; Rohan de Silva; Lester I Binder; David Morgan; Jada Lewis
Journal:  Am J Pathol       Date:  2008-12-12       Impact factor: 4.307

9.  Analysis of isoform-specific tau aggregates suggests a common toxic mechanism involving similar pathological conformations and axonal transport inhibition.

Authors:  Kristine Cox; Benjamin Combs; Brenda Abdelmesih; Gerardo Morfini; Scott T Brady; Nicholas M Kanaan
Journal:  Neurobiol Aging       Date:  2016-07-29       Impact factor: 4.673

10.  A possible link between astrocyte activation and tau nitration in Alzheimer's disease.

Authors:  Juan F Reyes; Matthew R Reynolds; Peleg M Horowitz; Yifan Fu; Angela L Guillozet-Bongaarts; Robert Berry; Lester I Binder
Journal:  Neurobiol Dis       Date:  2008-05-02       Impact factor: 5.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.